MBCC 2010 header

Publication
Article

Exclusive coverage of the 27th annual Miami Breast Cancer Conference includes expert perspectives, abstract reviews, interviews and more.

Perspective and Highlights from the 27th Annual Miami Breast Cancer Conference

Clinical quandary in adjuvant chemo: Endpoint versus toxicity

“Father of tamoxifen” foresees challenges and successes for endocrine therapy

More Coverage from MBCC 2010

Recent Videos
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
2 experts are featured in this series.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Related Content
Investigators will present topline data from the phase 2/3 study of uproleselan/chemotherapy at a future medical meeting.

Uproleselan Combo Does Not Improve EFS Vs Chemo in Newly Diagnosed AML

Russ Conroy
October 30th 2024
Article

Investigators will present topline data from the phase 2/3 study of uproleselan/chemotherapy at a future medical meeting.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Empowering Awareness to Address Rising Gynecological Cancer Incidence

Ginger J. Gardner, MD, FACOG
October 28th 2024
Podcast

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202

Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202

American Society for Transplantation and Cellular Therapy
October 30th 2024
Article

Posttransplant cyclophosphamide leads to unique changes in vascular biomarkers, revealing a distinct toxicity profile compared to other GVHD prophylaxis regimens.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Data from the AcceleRET-Lung trial show an imbalanced risk of severe and fatal infection with pralsetinib for patients with RET fusion-positive NSCLC.

Letter from Rigel Points to New Safety Signal of Pralsetinib in RET+ NSCLC

Russ Conroy
October 30th 2024
Article

Data from the AcceleRET-Lung trial show an imbalanced risk of severe and fatal infection with pralsetinib for patients with RET fusion-positive NSCLC.

Data from the ASC4FIRST trial support the accelerated approval of asciminib in this CML population.

FDA Grants Accelerated Approval to Asciminib in Ph+ CML in Chronic Phase

Russ Conroy
October 29th 2024
Article

Data from the ASC4FIRST trial support the accelerated approval of asciminib in this CML population.